| Literature DB >> 29743665 |
Hideki Tatsukawa1, Risa Otsu2, Yuji Tani2, Ryosuke Wakita2, Kiyotaka Hitomi2.
Abstract
Chronic kidney disease is characterized by prolonged decline in renal function, excessive accumulation of ECM, and progressive tissue fibrosis. Transglutaminase (TG) is a crosslinking enzyme that catalyzes the formation of covalent bonds between glutamine and lysine residues, and is involved in the induction of renal fibrosis via the stabilization of ECM and the activation of TGF-β1. Despite the accumulating evidences indicating that TG2 is a key enzyme in fibrosis, genetic knockout of TG2 reduced by only 50% the elevated protein crosslinking and fibrous protein in renal fibrosis model, whereas treatment with TG inhibitor almost completely reduced these levels. Here, we also clarified the distributions of TG isozymes and their in situ activities and identified the isozyme-specific crosslinked substrates for both TG1 and TG2 in fibrotic kidney. We found that TG1 activity was markedly enhanced in renal tubular epithelium and interstitial areas, whereas TG2 activity increased only in the extracellular space. In total, 47 and 67 possible candidates were identified as TG1 and TG2 substrates, respectively, only in fibrotic kidney. Among them, several possible substrates related to renal disease and fibrosis were identified. These findings provide novel insights into the mechanisms of renal fibrosis through the targeting of isozyme-specific TG substrates.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29743665 PMCID: PMC5943318 DOI: 10.1038/s41598-018-25674-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Evaluation of the fibrotic markers in kidney fibrosis after UUO surgery. UUO was induced in mice by ligating the left ureter in 8 weeks-old ICR mice. The mice were then sacrificed on days 3, 7, and 14 after surgery (n = 7–10 mice per group). (A) Kidney sections were fixed in 4% paraformaldehyde, and then stained using H&E and Sirius Red (using the Sirius Red Collagen Detection Kit). The red and green colors indicate the fibrillar collagen (type I to V collagen) and non-collagenous protein, respectively. Bar = 100 μm. (B) Hydroxyproline (HDP) contents were evaluated in the kidney on each indicated day after UUO surgery. The data are presented as the mean ± SD (n = 3) (**P < 0.01, Student’s t-test). (C) The mRNA expression levels of the fibrotic markers (Collagen Iα1 (Col1a1), α-SMA, TGF-β1, and GAPDH) were confirmed by RT-PCR. The full-length gel is presented in Fig. S1. (D) The protein levels in the whole lysate from the kidney tissue were analyzed by immunoblotting using each indicated antibody and GAPDH as a loading control for each sample. The full-length gel is presented in Fig. S2. (E–G) Relative changes in the densitometric profiles of collagen I, E-cadherin (E-cad), and α-SMA from (D) are presented under corresponding bands after normalizing to the changes in GAPDH. The data are presented as the mean ± SD (n = 4–5) (**P < 0.01, *P < 0.05, Student’s t-test).
Figure 2Expression levels of mRNA and protein of TG family in kidney fibrosis. (A) The mRNA expression levels of the TG family (FXIIIA and TG1–7) were confirmed by RT-PCR. The successful detections for TG3–6 using each primer pair are confirmed in the other tissue extracts. The full-length gels are presented in Fig. S3. (B) The protein levels in the whole lysate from the kidney tissue were analyzed by immunoblotting using each indicated antibody and GAPDH as a loading control for each sample. The full-length blot is presented in Fig. S4. (C,D) Relative changes in the densitometric profiles of TG1 and TG2 levels from (B) are presented under corresponding bands after normalizing to the changes in GAPDH. The data are presented as the mean ± SD (n = 3) (**P < 0.01, *P < 0.05, Student’s t-test).
Figure 3Distributions of the expressions and activities of TG1 and TG2 in fibrotic kidneys. Each kidney section was subjected to the immunohistochemistry and in situ TG activity staining on the indicated days after UUO surgery. (A) Immunostaining was performed using polyclonal anti-mouse TG1 and TG2 antibodies, and rabbit NI-IgG as the negative control. Three kinds of arrowheads indicate the areas where staining is changing for TG1 and TG2 such as tubule basement membrane and lumen (white arrowheads), tubular epithelial cells (black arrowheads), and interstitial areas (red arrowheads). Bar = 50 μm. (B) The in situ activities of TG1 and TG2 were visualized using FITC-labeled substrate peptides (pepK5 and pepT26, respectively). The white frame and white arrowheads indicated the notable tubular epithelial cells and interstitial areas, respectively. Bar = 50 μm. The relative intensities from (A) and (B) were presented in (C) and (D), respectively. The data are presented as the mean ± SD (n = 4) (**P < 0.01, Student’s t-test).
Figure 4Detailed distribution analysis of the enhanced activities of TG1 and TG2. The colocalization of the activity of each TG with the E-cadherin or type I collagen in the kidney sections was analyzed in the control and at 3 days after UUO surgery. (A,B) The kidney sections were incubated with FITC-labeled substrate peptides. Following fixation in 4% paraformaldehyde, the sections were immunostained using anti-E-cadherin antibody and counterstained with DAPI. Merged staining images are shown in the bottom lane, with arrowhead indicating the similar distributions between E-cadherin and each TG. Bars = 25 μm. (C,D) The kidney sections were incubated with FITC-labeled substrate peptides. Following fixation in 4% paraformaldehyde, the sections were immunostained using anti-collagen type 1A1 antibody and counterstained using DAPI. Merged staining images are shown in the bottom lane, with arrow indicating the different distributions between collagen and each TG. Bars = 25 μm. (E-H) The relative fluorescence intensities from (A–D) were presented. The data are presented as the mean ± SD (n = 6–8) (**P < 0.01, Student’s t-test).
Figure 5The effect of TGs inhibitor or genetic defect of TG2 during renal fibrosis. Cystamine, a competitive inhibitor for the crosslinking activity of TGs, was orally administrated in drinking water (approximately 8.75 mg/kg/day) from 2 days before the UUO surgery (n = 9–12 mice per group). At 14 days after UUO, the fibrotic kidney was collected and evaluated for collagen deposition. (A) The kidney sections were stained using a Sirius Red Collagen Detection Kit. The red and green colors indicate the fibrillar collagen (type I to V collagen) and non-collagenous protein, respectively. Bar = 100 μm. (B) The relative intensity of contents was also evaluated in the same kidney tissues. The data are presented as the mean ± SD (n = 4) (**P < 0.01, Student’s t-test). (C) The protein levels in the whole lysate of kidney tissue from cystamine-administrated mice were analyzed by immunoblotting using each indicated antibody and GAPDH as a loading control for each sample. The bands of collagen I in the position of high molecular weight (HMW) were separately presented in this figure. The full-length gel is presented in Fig. S6. (D–G) Relative changes in the densitometric profiles of collagen I, E-cadherin, and α-SMA from (C) are presented under corresponding bands after normalizing to the changes in GAPDH. The data are presented as the mean ± SD (n = 6–7) (*P < 0.05, Student’s t-test). (H) The wild-type and TG2KO mice were sacrificed on days 3, 7, and 14 after UUO surgery (n = 6–8 mice per group). The HDP contents were evaluated in the kidney on each indicated day after UUO surgery. The data are presented as the mean ± SD (n = 3) (*P < 0.05, Student’s t-test). (I) The protein levels in the whole lysate of kidney tissue from the WT and TG2KO mice after UUO surgery were analyzed by immunoblotting using each indicated antibody and GAPDH as a loading control for each sample. The full-length gel is presented in Fig. S7. (J–L) Relative changes in the densitometric profiles from (D) are presented under corresponding bands after normalizing to the changes in GAPDH. The data are presented as the mean ± SD (n = 3–4) (**P < 0.01, *P < 0.05, Student’s t-test).
Figure 6The effect of TGs inhibitor or knockdown of TG1 and TG2 in renal tubular epithelial cells. (A,B) Human tubular epithelial cells (HK-2) were plated in 6 cm dish (3 × 105 cells) and treated with 5 ng/ml TGF-β1 in the presence or absence of 1 mM cystamine in serum-free medium for 12 h. (C–H) For the knockdown of specific gene, siRNA mixture against TG1 (C–E) or TG2 (F–H) were added on the culture dish before seeding the cells. As a negative control, scrambled siRNA (Random) was replaced with the same amount of siRNA against TG1 and TG2. Then, after 24 h incubation, cells were treated with TGF-β1 for 12 h. Total mRNA were isolated and the indicated mRNA levels were evaluated using quantitative RT-PCR. Data were normalized against GAPDH mRNA expression and relative value (a ratio of the control sample) were presented as the mean ± SD (n = 3) (**P < 0.01, *P < 0.05, Student’s t-test).
Figure 7Detection of possible substrates incorporated with each peptide in kidney extracts. Each kidney extract on the indicated days after UUO surgery was incubated with the biotinylated pepK5 (for TG1; A) and pepT26 (for TG2; B). These biotinylated peptide-incorporated proteins after the purification using monoavidin gel were subjected to silver staining or detection using peroxidase-conjugated streptavidin. The sizes of the protein mass markers are shown on the left. Arrowheads indicate the bands that increased compared with the control sample (Day 0). Each experiment was done with more than three replicates from at least three independent experiments.
Identified possible substrates for TG1 using pepK5.
| Accession number | Name | Days | |||
|---|---|---|---|---|---|
| 0 | 3 | 7 | 14 | ||
| P01029 | Complement C4-B | + | + | + | |
| Q8K0E8 | Fibrinogen β chain | + | + | + | |
| Q922U2 | Keratin, type II cytoskeletal 5 | + | + | + | |
| P31725 | Protein S100-A9 | + | + | + | |
| Q921I1 | Serotransferrin | + | + | + | |
|
|
| + | + | + | |
| P99024 | Tubulin β-5 chain | + | + | + | |
|
|
| + | + | ||
|
|
| + | + | ||
| Q68FD5 | Clathrin heavy chain 1 | + | + | ||
| O35737 | Heterogeneous nuclear ribonucleoprotein H | + | + | ||
| P62737 | Actin, aortic smooth muscle | + | + | ||
| P06909 | Complement factor H | + | + | ||
| Q8VCM7 | Fibrinogen γ chain | + | + | ||
| Q9Z2X1 | Heterogeneous nuclear ribonucleoprotein F | + | + | ||
| Q91X17 | Uromodulin | + | + | ||
| Q8CGP1 | Histone H2B type 1-K | + | |||
| P62960 | Nuclease-sensitive element-binding protein 1 | + | |||
| Q9WV32 | Actin-related protein 2/3 complex subunit 1B | + | |||
| Q8BSL7 | ADP-ribosylation factor 2 | + | |||
| Q8JZQ5 | Amiloride-sensitive amine oxidase [copper-containing] | + | |||
| P10126 | Elongation factor 1-α 1 | + | |||
| P16110 | Galectin-3 | + | |||
| P11499 | Heat shock protein HSP 90-β | + | |||
| P02104 | Hemoglobin subunit ε-Y2 | + | |||
| Q99020 | Heterogeneous nuclear ribonucleoprotein A/B | + | |||
| Q8VEK3 | Heterogeneous nuclear ribonucleoprotein U | + | |||
| Q8CGP7 | Histone H2A type 1-K | + | |||
| P10854 | Histone H2B type 1-M | + | |||
| O89017 | Legumain | + | |||
| P26041 | Moesin | + | |||
| P17225 | Polypyrimidine tract-binding protein 1 | + | |||
| Q61656 | Probable ATP-dependent RNA helicase DDX5 | + | |||
| P26043 | Radixin | + | |||
| Q62093 | Splicing factor, arginine/serine-rich 2 | + | |||
|
|
| + | |||
| P26039 | Talin-1 | + | |||
| Q9CWF2 | Tubulin β-2B chain | + | |||
|
|
| + | |||
| P63268 | Actin, γ-enteric smooth muscle | + | |||
| Q60847 | Collagen α-1(XII) chain | + | |||
| P01942 | Hemoglobin subunit α | + | |||
| P02089 | Hemoglobin subunit β-2 | + | |||
| P01873 | Ig mu chain C region membrane-bound form | + | |||
| P08071 | Lactotransferrin | + | |||
| P11247 | Myeloperoxidase | + | |||
| P68369 | Tubulin α-1A chain | + | |||
Kidney extract on each indicated day after UUO surgery was incubated with biotinylated pepK5. The newly identified possible substrates in each indicated day were demonstrated as “+” compared to control sample (Day 0). The underlined possible substrates indicate overlapped substrates identified as both peptide (pepK5 and pepT26)-incorporated proteins. This Each experiment was done with two replicates from three independent experiments.
Identified possible substrates for TG2 using pepT26.
| Accession number | Name | Days | |||
|---|---|---|---|---|---|
| 0 | 3 | 7 | 14 | ||
| O08756 | 3-hydroxyacyl-CoA dehydrogenase type-2 | + | + | + | |
| P20060 | β-hexosaminidase subunit β | + | + | + | |
| P05064 | Fructose-bisphosphate aldolase A | + | + | + | |
| Q91Y97 | Fructose-bisphosphate aldolase B | + | + | + | |
| P54071 | Isocitrate dehydrogenase [NADP], mitochondrial | + | + | + | |
| P51660 | Peroxisomal multifunctional enzyme type 2 | + | + | + | |
| P31725 | Protein S100-A9 | + | + | + | |
| P26040 | Ezrin | + | + | ||
| P06909 | Complement factor H | + | + | ||
| P63017 | Heat shock cognate 71 kDa protein | + | + | ||
| O35737 | Heterogeneous nuclear ribonucleoprotein H | + | + | ||
| Q61781 | Keratin, type I cytoskeletal 14 | + | + | ||
| P08071 | Lactotransferrin | + | + | ||
| P45952 | Medium-chain specific acyl-CoA dehydrogenase, mitochondrial | + | + | ||
| P26041 | Moesin | + | + | ||
| Q99MZ7 | Peroxisomal trans-2-enoyl-CoA reductase | + | + | ||
| Q9WUA2 | Phenylalanyl-tRNA synthetase β chain | + | + | ||
| P84104 | Splicing factor, arginine/serine-rich 3 | + | + | ||
| P26443 | Glutamate dehydrogenase 1, mitochondrial | + | + | ||
| Q9WVE8 | Protein kinase C and casein kinase substrate in neurons protein 2 | + | + | ||
|
|
| + | + | ||
| P99024 | Tubulin β-5 chain | + | + | ||
| Q60597 | 2-oxoglutarate dehydrogenase, mitochondrial | + | |||
| Q9D8E6 | 60 S ribosomal protein L4 | + | |||
| P62897 | Cytochrome c, somatic | + | |||
| Q99LB2 | Dehydrogenase/reductase SDR family member 4 | + | |||
| P58252 | Elongation factor 2 | + | |||
| Q64525 | Histone H2B type 2-B | + | |||
| Q9ERE2 | Keratin, type II cuticular Hb1 (Fragment) | + | |||
|
|
| + | |||
| Q9ERD7 | Tubulin β-3 chain | + | |||
|
|
| + | |||
| Q6ZWV3 | 60 S ribosomal protein L10 | + | |||
|
|
| + | |||
| P48962 | ADP/ATP translocase 1 | + | |||
| Q03265 | ATP synthase subunit α, mitochondrial | + | |||
| P56480 | ATP synthase subunit β, mitochondrial | + | |||
| Q8BFZ3 | β-actin-like protein 2 | + | |||
| P16858 | Glyceraldehyde-3-phosphate dehydrogenase | + | |||
| P30681 | High mobility group protein B2 | + | |||
| Q9D646 | Keratin, type I cuticular Ha4 | + | |||
| Q6IMF0 | Keratin, type II cuticular Hb3 | + | |||
| Q8R429 | Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 | + | |||
| P05214 | Tubulin α-3 chain | + | |||
| P68372 | Tubulin β-2C chain | + | |||
| P28653 | Biglycan | + | |||
| Q9CZU6 | Citrate synthase, mitochondrial | + | |||
| Q9QZQ8 | Core histone macro-H2A.1 | + | |||
| Q99020 | Heterogeneous nuclear ribonucleoprotein A/B | + | |||
| Q9Z130 | Heterogeneous nuclear ribonucleoprotein D-like | + | |||
| Q9Z2X1 | Heterogeneous nuclear ribonucleoprotein F | + | |||
| Q8VEK3 | Heterogeneous nuclear ribonucleoprotein U | + | |||
| P63158 | High mobility group protein B1 | + | |||
|
|
| + | |||
| Q9D2U9 | Histone H2B type 3-A | + | |||
| P84244 | Histone H3.3 | + | |||
| P62960 | Nuclease-sensitive element-binding protein 1 | + | |||
| P09405 | Nucleolin | + | |||
| Q8BK67 | Protein RCC2 | + | |||
| P27005 | Protein S100-A8 | + | |||
| P54276 | REVERSED DNA mismatch repair protein Msh6 | + | |||
| Q921I1 | Serotransferrin | + | |||
| P26039 | Talin-1 | + | |||
| Q9D0R2 | Threonyl-tRNA synthetase, cytoplasmic | + | |||
| Q9CWF2 | Tubulin beta-2B chain | + | |||
| Q91X17 | Uromodulin | + | |||
| P50544 | Very long-chain specific acyl-CoA dehydrogenase, mitochondrial | + | |||
Kidney extract on each indicated day after UUO surgery was incubated with biotinylated pepT26. The newly identified possible substrates in each indicated day were demonstrated as “+” compared to control sample (Day 0). The underlined possible substrates indicate overlapped substrates identified as both peptide (pepK5 and pepT26)-incorporated proteins.
Figure 8Gene ontology (GO) terms for possible substrates for TG1 and TG2 during renal fibrosis. GO analysis corresponding to biological process (A), molecular function (B) and PANTHER protein class (C) represented as pie and bar charts generated by PANTHER classification system (http://www.pantherdb.org/).
Primer pairs for RT-PCR experiments using mouse renal tissue.
| Gene | Forward | Reverse | Product size |
|---|---|---|---|
|
| GAGCGGAGAGTACTGGATCG | TACTCGAACGGGAATCCATC | 204 |
|
| ACTGGGACGACATGGAAAAG | AGAGGCATAGAGGGACAGCA | 203 |
|
| ATACGCCTGAGTGGCTGTCT | GGTTCATGTCATGGATGGTG | 192 |
|
| TGATTGTCCGCAGAGGGCAG | GGGTAGCGACCAATGAC | 105 |
|
| ATCGTGGTAGTAGCCGACGC | ATGGTCACAGAGTCCGAGGC | 138 |
|
| AGCCGATGATGTGTACCTAG | AGGATTCCATCCTCGAACTG | 137 |
|
| TGGAGAAAGGCAGTGATAG | ACTGGAACCTTCTGGATAC | 382 |
|
| AGTCTGGCGTAGAGGTTATTC | CCTGAGCACCACGGATTG | 125 |
|
| GTTCCATTCTGGCAGGACAC | CCCAGGGCACTGATGCGGAT | 133 |
|
| GCTCTGTGCTTGACCAACCT | TGGGATTCACGCAGGATCTC | 112 |
|
| ACAGGGCAGTTCATTCTGGT | TGGTGAGGGTGATGTGGATA | 117 |
|
| ACTGGCATGGCCTTCCGTGT | CCTGCTTCACCACCTTCTTG | 109 |
Primer pairs for quantitative RT-PCR experiments using human tubular epithelial cell.
| Gene | Forward | Reverse | Product size |
|---|---|---|---|
|
| CCTGCGTGTACCCCACTCA | ACCAGACATGCCTCTTGTCCTT | 83 |
|
| GAACGCATTGCCACATACAC | ATTCGGGCTTGTTGTCATTC | 118 |
|
| TGCCCAGAGGACATTGTGTA | GTGGTCAAACTGGCCGTAGT | 135 |
|
| ATGCCGACGTGGTAGACTGG | CACTGCCCATGTTCATGCTC | 270 |
|
| ACTGGCATGGCCTTCCGTGT | CCTGCTTCACCACCTTCTTG | 109 |